Date: 2015-06-24
Type of information: Initiation of the trial
phase: preclinical
Announcement: initiation of preclinical development
Company: Neurotrope BioScience (USA - NJ)
Product: bryostatin
Action mechanism:
Disease: Niemann-Pick disease type C
Therapeutic area: Rare diseases - Genetic diseases
Country:
Trial details:
Latest
news: * On June 24, 2015, Neurotrope announced that Neurotrope Bioscience, Inc., its operating wholly-owned subsidiary will conduct a preclinical study, in collaboration with a leading research institution, to examine the effect of bryostatin in Niemann-Pick type C (NPC) mice. The study is being funded by several family foundations under the auspices of Support Of Accelerated Research for NPC Disease (“SOAR-NPC”). This planned study will examine the effects of various dosing regimens of bryostatin in NPC mice over a brief treatment period. Specifically, the in vivo study will seek to confirm previous in vitro studies that suggest bryostatin may be effective in correcting the cholesterol transport defect in NPC. Neurotrope expects the results of the study to be available in the third quarter of 2015. “This study is designed to examine the ability of bryostatin treatment to remove cholesterol from the brain which is critical for an effective therapy of NPC” stated Dr. Warren W. Wasiewski, Neurotrope’s Chief Medical Officer.
